XBiotech announces completion of U.S. enrollment in phase 2 study evaluating bermekimab
XBiotech announced it had completed enrollment in the U.S. for its Phase 2, open label clinical study evaluating subcutaneous administration of bermekimab in patients with moderate to severe Hidradenitis Suppurativa. Enrollment has exceeded the planned limit. September 24, 2018